CompletedNCT03448016
[C-11]NOP-1A and Addiction
Medication studyAges 18–55United States
Understand this study
Who was this study for?
Listed age limits: 18 years to 55 years.
- Listed locations
- PittsburghSee all locations and recruitment
- Study phase
- Early phase 1An early first-in-human or very early safety study, usually focused on how a treatment behaves in the body.
Study information
Study start dateStarted: May 27, 2016
- Recruitment status
- Completed
- Enrollment listed in the registry
- 54
- Sponsor
- Rajesh Narendran
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Medication / drug, RADIATION
- Study phase
- EARLY Phase 1An early first-in-human or very early safety study, usually focused on how a treatment behaves in the body.
- Locations
- United States
- Age range
- From 18 Years to 55 Years
- Official registry ID
- NCT03448016
- Official title
Show the full official title
Linking Nociceptive Opioid Peptide (NOP) Receptors With Relapse in Alcoholism
Get this study by email
Recruitment & locations
CompletedPittsburgh
Questions about this study
Who is behind this study?
The study sponsor is Rajesh Narendran.
Did this study involve medication?
Yes. The study involved medication, including NOP-1A.
Who was this study for?
Listed age limits: 18 years to 55 years.
Want to explore more studies?
Explore studiesRelated studies
[11C]NOP-1A and Cocaine Use Disorders
[C-11]PiB PET Imaging in Alcohol Use Disorders